<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596817</url>
  </required_header>
  <id_info>
    <org_study_id>11985A</org_study_id>
    <secondary_id>2007-001871-13</secondary_id>
    <nct_id>NCT00596817</nct_id>
  </id_info>
  <brief_title>Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Two Doses of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of Vortioxetine in the prevention of relapse of major
      depressive episodes in patients who responded to open-label treatment with Vortioxetine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score &gt;=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator</measure>
    <time_frame>Within first 24 weeks of the double-blind period</time_frame>
    <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse During the Entire Double-blind Period Based on a MADRS Total Score &gt;=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator</measure>
    <time_frame>Within 64 weeks of the double-blind period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Double-blind Baseline in MADRS Total Score After 24 Weeks of Double-blind Treatment</measure>
    <time_frame>Double-blind Baseline and Week 24 of the double-blind period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Double-blind Baseline in HAM-D-17 Total Score After 24 Weeks of Double-blind Treatment</measure>
    <time_frame>Double-blind Baseline and Week 24 of the double-blind period</time_frame>
    <description>The Hamilton Depression Scale - 17 items (HAM-D-17) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 52. The higher the score, the more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Double-blind Baseline in HAM-A Total Score After 24 Weeks of Double-blind Treatment</measure>
    <time_frame>Double-blind Baseline and Week 24 of the double-blind period</time_frame>
    <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Double-blind Baseline in CGI-S Score After 24 Weeks of Double-blind Treatment</measure>
    <time_frame>Double-blind Baseline and Week 24 of the double-blind period</time_frame>
    <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Responders at Week 24 of the Double-blind Period (Response Defined as a &gt;=50% Reduction in MADRS Total Score From Open-label Baseline)</measure>
    <time_frame>Week 24 of the double-blind period (Counted From Open-label Baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Remitters at Week 24 of the Double-blind Period (Remission Defined as a MADRS Total Score &lt;=10)</measure>
    <time_frame>Week 24 of the double-blind period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Double-blind Baseline in SDS Total Score at Week 24 of the Double-blind Period</measure>
    <time_frame>Week 24 of the double-blind period (Counted From Double-blind Baseline)</time_frame>
    <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">639</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine: 5 or 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsules, daily, orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine (Lu AA21004)</intervention_name>
    <description>encapsulated tablets, daily, orally</description>
    <arm_group_label>Vortioxetine: 5 or 10 mg</arm_group_label>
    <other_name>Brintellix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major Depressive Episode (MDE) as the primary diagnosis according to DSM-IV TR
             criteria

          -  At least one other MDE before the current one

          -  Moderate to severe depression

        Exclusion Criteria:

          -  Any current psychiatric disorder other than Major Depressive Disorder (MDD) as defined
             in the DSM-IV TR

          -  Any substance disorder within the previous 6 months

          -  Female patients of childbearing potential who are not using effective contraception

          -  Use of any psychoactive medication 2 weeks prior to screening and during the study

        Randomisation Criteria: Patients in remission (MADRS total score &lt;=10) at both Week 10 and
        Week 12

        Other protocol-defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </removed_countries>
  <results_reference>
    <citation>Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012 Nov;26(11):1408-16. doi: 10.1177/0269881112441866. Epub 2012 Apr 9.</citation>
    <PMID>22495621</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <results_first_submitted>October 28, 2013</results_first_submitted>
  <results_first_submitted_qc>February 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2014</results_first_posted>
  <last_update_submitted>February 13, 2014</last_update_submitted>
  <last_update_submitted_qc>February 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapse prevention</keyword>
  <keyword>Antidepressants</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Double-blind</keyword>
  <keyword>Multicentre study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were in- and outpatients from psychiatric settings.</recruitment_details>
      <pre_assignment_details>The study consisted of two consecutive periods: a 12-week open-label treatment period with Vortioxetine and a double-blind, fixed-dose, placebo-controlled treatment period of at least 24 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo : capsules, daily, orally</description>
        </group>
        <group group_id="P2">
          <title>Vortioxetine: 5 or 10 mg</title>
          <description>Vortioxetine (Lu AA21004) : encapsulated tablets, daily, orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="639"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="492"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Period to Double-blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="492"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="400"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Eligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192">194 patients were randomised. 2 did not receive study medication. 192 is full-analysis set (FAS).</participants>
                <participants group_id="P2" count="204">206 patients were randomised. 2 did not receive study medication. 204 is FAS.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance With Study Product</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The total number of patients under Baseline Measures is not 1035 as automatically calculated, but 639 as stated in the &quot;Open-label Period (APTS)&quot; column and 396 in the “Double-blind Period (FAS)”.
The &quot;Total&quot; column of each Baseline Measure is Double-blind Period (FAS).</population>
      <group_list>
        <group group_id="B1">
          <title>Open-label Period (APTS)</title>
        </group>
        <group group_id="B2">
          <title>Placebo - Double-blind Period (FAS)</title>
          <description>Placebo : capsules, daily, orally</description>
        </group>
        <group group_id="B3">
          <title>Vortioxetine: 5 or 10 mg - Double-blind Period (FAS)</title>
          <description>Vortioxetine (Lu AA21004) : encapsulated tablets, daily, orally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="639"/>
            <count group_id="B2" value="192"/>
            <count group_id="B3" value="204"/>
            <count group_id="B4" value="1035"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="12.4"/>
                    <measurement group_id="B2" value="45.1" spread="12.1"/>
                    <measurement group_id="B3" value="44.8" spread="12.4"/>
                    <measurement group_id="B4" value="45.0" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female (Open-label Period)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="397"/>
                    <measurement group_id="B2" value="NA">Only data for Open-label Period</measurement>
                    <measurement group_id="B3" value="NA">Only data for Open-label Period</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male (Open-label Period)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="NA">Only data for Open-label Period</measurement>
                    <measurement group_id="B3" value="NA">Only data for Open-label Period</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female (Double-blind Period)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male (Double-blind Period)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MADRS</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.3" spread="4.1"/>
                    <measurement group_id="B2" value="4.66" spread="3.16"/>
                    <measurement group_id="B3" value="4.89" spread="3.00"/>
                    <measurement group_id="B4" value="4.78" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAM-D-17</title>
          <description>The Hamilton Depression Scale – 17 items (HAM-D-17) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 52. The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.8" spread="4.5"/>
                    <measurement group_id="B2" value="3.96" spread="3.15"/>
                    <measurement group_id="B3" value="4.46" spread="3.27"/>
                    <measurement group_id="B4" value="4.21" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAM-A</title>
          <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.6" spread="6.6"/>
                    <measurement group_id="B2" value="4.60" spread="3.60"/>
                    <measurement group_id="B3" value="5.09" spread="3.83"/>
                    <measurement group_id="B4" value="4.85" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGI-S</title>
          <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="0.7"/>
                    <measurement group_id="B2" value="1.54" spread="0.69"/>
                    <measurement group_id="B3" value="1.56" spread="0.68"/>
                    <measurement group_id="B4" value="1.55" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SDS</title>
          <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" spread="5.7"/>
                    <measurement group_id="B2" value="8.37" spread="7.44"/>
                    <measurement group_id="B3" value="8.95" spread="7.09"/>
                    <measurement group_id="B4" value="8.66" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score &gt;=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator</title>
        <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
        <time_frame>Within first 24 weeks of the double-blind period</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine: 5 or 10 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score &gt;=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
          <population>FAS</population>
          <units>percentage of patients who relapsed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <method>Cox-model</method>
            <method_desc>Cox-model using an exact method to handle ties</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>3.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse During the Entire Double-blind Period Based on a MADRS Total Score &gt;=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator</title>
        <time_frame>Within 64 weeks of the double-blind period</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine: 5 or 10 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse During the Entire Double-blind Period Based on a MADRS Total Score &gt;=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator</title>
          <population>FAS</population>
          <units>percentage of patients who relapsed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Cox-Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>3.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Double-blind Baseline in MADRS Total Score After 24 Weeks of Double-blind Treatment</title>
        <time_frame>Double-blind Baseline and Week 24 of the double-blind period</time_frame>
        <population>FAS; observed cases (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine: 5 or 10 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-blind Baseline in MADRS Total Score After 24 Weeks of Double-blind Treatment</title>
          <population>FAS; observed cases (OC)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.55"/>
                    <measurement group_id="O2" value="-0.62" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.36</ci_lower_limit>
            <ci_upper_limit>-0.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Double-blind Baseline in HAM-D-17 Total Score After 24 Weeks of Double-blind Treatment</title>
        <description>The Hamilton Depression Scale – 17 items (HAM-D-17) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 52. The higher the score, the more severe.</description>
        <time_frame>Double-blind Baseline and Week 24 of the double-blind period</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine: 5 or 10 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-blind Baseline in HAM-D-17 Total Score After 24 Weeks of Double-blind Treatment</title>
          <description>The Hamilton Depression Scale – 17 items (HAM-D-17) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 52. The higher the score, the more severe.</description>
          <population>FAS; OC</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.46"/>
                    <measurement group_id="O2" value="0.30" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0171</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Double-blind Baseline in HAM-A Total Score After 24 Weeks of Double-blind Treatment</title>
        <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.</description>
        <time_frame>Double-blind Baseline and Week 24 of the double-blind period</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine: 5 or 10 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-blind Baseline in HAM-A Total Score After 24 Weeks of Double-blind Treatment</title>
          <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.</description>
          <population>FAS; OC</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.50"/>
                    <measurement group_id="O2" value="-0.23" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0612</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Double-blind Baseline in CGI-S Score After 24 Weeks of Double-blind Treatment</title>
        <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.</description>
        <time_frame>Double-blind Baseline and Week 24 of the double-blind period</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine: 5 or 10 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-blind Baseline in CGI-S Score After 24 Weeks of Double-blind Treatment</title>
          <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.</description>
          <population>FAS; OC</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.08"/>
                    <measurement group_id="O2" value="-0.14" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Responders at Week 24 of the Double-blind Period (Response Defined as a &gt;=50% Reduction in MADRS Total Score From Open-label Baseline)</title>
        <time_frame>Week 24 of the double-blind period (Counted From Open-label Baseline)</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine: 5 or 10 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Responders at Week 24 of the Double-blind Period (Response Defined as a &gt;=50% Reduction in MADRS Total Score From Open-label Baseline)</title>
          <population>FAS; OC</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7"/>
                    <measurement group_id="O2" value="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Difference</param_type>
            <param_value>6.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>11.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Remitters at Week 24 of the Double-blind Period (Remission Defined as a MADRS Total Score &lt;=10)</title>
        <time_frame>Week 24 of the double-blind period</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine: 5 or 10 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Remitters at Week 24 of the Double-blind Period (Remission Defined as a MADRS Total Score &lt;=10)</title>
          <population>FAS; OC</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Difference</param_type>
            <param_value>12.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.73</ci_lower_limit>
            <ci_upper_limit>19.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Double-blind Baseline in SDS Total Score at Week 24 of the Double-blind Period</title>
        <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
        <time_frame>Week 24 of the double-blind period (Counted From Double-blind Baseline)</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine: 5 or 10 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-blind Baseline in SDS Total Score at Week 24 of the Double-blind Period</title>
          <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
          <population>FAS; OC</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.58"/>
                    <measurement group_id="O2" value="-0.53" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3642</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.12</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events: 12-week open-label period, 24-week double-blind period and 4-week safety follow-up period. Other Adverse Events: 12-week open-label period and 24-week double-blind period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open-label Period (APTS)</title>
        </group>
        <group group_id="E2">
          <title>Placebo - Double-blind Period (FAS)</title>
        </group>
        <group group_id="E3">
          <title>Vortioxetine: 5 or 10 mg - Double-blind Period (FAS)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA12_0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Sebaceous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA12_0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="337" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <description>Everything beyond the prescribed dose, for instance one extra tablet, is counted as an overdose.</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The main publication has to be published before any sub-publications. H. Lundbeck A/S follows the Vancouver declaration with respect to authorship.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H. Lundbeck A/S</name_or_title>
      <organization>H. Lundbeck A/S</organization>
      <email>LundbeckClinicalTrials@lundbeck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

